Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension
NCT ID: NCT04554303
Last Updated: 2020-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2020-10-28
2022-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Edema, one of the most common side effects of dihydropyridine CCB formulations, may lead to drug control or discontinuation of drugs.
This clinical study intends to assess the safety and efficacy of S-amlodipine, which is assessed to be superior to Amlodipine in the aspects of antihypertensive effect and side effects, in edema of patients with essential hypertension.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\- In this clinical study, Part 1 is conducted as a preliminary study on 10 subjects at a single center, and based on the results of Part 1, the sponsor and the principal investigator determine whether to proceed with Part 2. With Part 2 as the multicenter main study conducted on the remaining 70 subjects, 80 subjects in total have been planned for Part 1 and Part 2.
2. Interim analysis
\- The interim analysis is conducted when the study on 10 subjects at a Part 1 single center has been completed; the analysis is made on all endpoints planned for this clinical study.
3. Clinical study methods - During screening, subjects who have voluntarily signed the Informed Consent Form are tested for eligibility to this clinical study.
After a wash-out period of at least two weeks, subjects who satisfy the inclusion/exclusion criteria are randomly assigned to two groups (S-amlodipine group, Amlodipine group). Thereafter, the subjects are enrolled and orally administered with the investigational product once a day for 12 weeks, during which they receive a total of five visits for tests conducted for assessment of efficacy and safety.
(In case of confirmed eligibility without administration of contraindications, the wash-out period may be omitted and Visits 1 and 2 may be paid on the same day)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
S-amlodipine treatment group
Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
S-amlodipine 2.5mg
Oral administration, 1 tablet per day
Amlodipine treatment group
Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
Amlodipine 5mg
Oral administration, 1 tablet per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
S-amlodipine 2.5mg
Oral administration, 1 tablet per day
Amlodipine 5mg
Oral administration, 1 tablet per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Where a subject and his/her spouse (partner) have agreed to use medically acceptable contraceptives in the following during participation in this clinical study:
* Use of intrauterine device with proven failure rate of pregnancy;
* Simultaneous use of blocking contraception and spermicide;
* Has had a vasectomy;
* Has had a salpingectomy, tubal ligation, or hysterectomy;
3. Those who have made voluntary decisions to participate in this clinical study and have consented to the Informed Consent Form in writing;
4. Those who are able to understand and follow instructions and participate throughout the entire clinical study
Exclusion Criteria
2. Those who have a history of secondary hypertension and any history of suspected secondary hypertension (aortic congestion, hyperaldosteronism, renal artery stenosis, Cushing's disease, chromaffinoma, polycystic renal disease, etc.);
3. Those who fall under one or more of the following items that may cause edema without underlying diseases:
* Those who have been diagnosed with myocardial infarction or heart failure within 6 months of screening;
* Those who have been diagnosed with a cerebrovascular accident (CVA) within 6 months of screening;
* Patients with renal failure requiring dialysis or those with edema caused by renal dysfunction (renal salt retention);
* Those who have uncontrolled diabetes (HbA1c\> 10.0%) or diabetic edema;
* Patients with severe liver dysfunction or edema caused by liver disease (cirrhosis);
* Other patients with hypothyroidism, proteinuria, and problems at the joint or ankle joint
4. Those who have cerebrovascular disease, unstable angina, or transient ischemic attack, or those who have had coronary artery bypass graft or coronary angioplasty;
5. Patients who may develop edema by concomitant drugs at screening:
* Drugs that constrict intrarenal blood vessels (e.g. nonsteroidal anti-inflammatory drugs, cyclosporine, etc.);
* Drugs that dilate arterioles (e.g. vasodilators, etc.);
* Drugs that increase sodium reabsorption in the kidneys (e.g. steroids, etc.);
* Drugs that damage capillaries (e.g. interleukin-2, etc.);
* Glitazone-based drugs for diabetes
6. Those who show hypersensitive reaction\* to the investigational product;
7. Those who are taking the following drugs that may cause drug interactions:
* Drugs that may change the plasma concentration of amlodipine \[e.g. CYP3A4 inducers (e.g. rifampicin, St. John's wort (Hypericum perforatum), etc.);
* Drugs that may increase the antihypertensive action \[e.g. other antihypertensives (calcium channel blockers, beta blockers, ACEi, ARB, alpha blockers, diuretics, nitroglycerin), tricyclic antidepressants (amitriptyline, desipramine, imipramine, nortriptyline, protriptyline, trimipramine, etc.), nitrate formulation, baclofen, pioglitazone, sildenafil, etc.\];
* Systemic corticosteroids (fluocinolone, triamcinolone), etc.: Local application allowed;
* Drugs that may increase the inhibitory action of muscle contraction \[e.g. antiarrhythmics (amiodarone, quinidine, etc.);
* Drugs that may cause ventricular spasms (e.g. intravenous administration of dantrolene and verapamil);
* Drugs that may increase the risk of hypotension \[e.g. CYP3A4 inhibitors (clarithromycin), etc.\]
8. Patients in a state of chronic inflammation requiring chronic anti-inflammatory treatment;
9. Those who have participated in other interventional clinical studies within 6 months of screening;
10. Those who have been diagnosed as having malignant tumors within 5 years of screening;
11. Those who showed clinically significant abnormal results in electrocardiogram and laboratory tests at screening;
12. Those who are pregnant or lactating, or have been confirmed as being pregnant through the Urine HCG test;
13. Those who have been judged to be inappropriate to participate in the clinical study by the principal investigator or subinvestigator.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University Guro Hospital
OTHER
Dt&Sanomedics
INDUSTRY
Ahn-Gook Pharmaceuticals Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eung Ju Kim, PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eung-Ju Kim, Ph.D
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Pathak L, Hiremath, Kerkar PG, Manade VG. Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial. J Assoc Physicians India. 2004 Mar;52:197-202.
Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000 Feb;35(2):621-5. doi: 10.1161/01.hyp.35.2.621.
Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002 Nov;4(6):479-82. doi: 10.1007/s11886-002-0110-9.
Sener D, Halil M, Yavuz BB, Cankurtaran M, Ariogul S. Anasarca edema with amlodipine treatment. Ann Pharmacother. 2005 Apr;39(4):761-3. doi: 10.1345/aph.1E410. Epub 2005 Feb 22.
Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998 Apr 14;97(14):1411-20. doi: 10.1161/01.cir.97.14.1411.
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007 Jan 20;369(9557):201-7. doi: 10.1016/S0140-6736(07)60108-1.
Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, Messerli FH. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011 Jul;29(7):1270-80. doi: 10.1097/HJH.0b013e3283472643.
Galappatthy P, Waniganayake YC, Sabeer MI, Wijethunga TJ, Galappatthy GK, Ekanayaka RA. Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial. BMC Cardiovasc Disord. 2016 Sep 1;16(1):168. doi: 10.1186/s12872-016-0350-z.
Liu F, Qiu M, Zhai SD. Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2010 Feb;71(1):1-29. doi: 10.1016/j.curtheres.2010.02.005.
Kim SA, Park S, Chung N, Lim DS, Yang JY, Oh BH, Tahk SJ, Ahn TH. Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial. Clin Ther. 2008 May;30(5):845-57. doi: 10.1016/j.clinthera.2008.05.013.
Schoeller DA, Alon A, Manekas D, Mixson LA, Lasseter KC, Noonan GP, Bolognese JA, Heymsfield SB, Beals CR, Nunes I. Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study. Clin Ther. 2012 Mar;34(3):580-92. doi: 10.1016/j.clinthera.2012.01.018. Epub 2012 Mar 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AG-C1908
Identifier Type: -
Identifier Source: org_study_id